China
Africa
Explore chapters and articles related to this topic
Contraception
Published in S Paige Hertweck, Maggie L Dwiggins, Clinical Protocols in Pediatric and Adolescent Gynecology, 2022
Segesterone acetate 103 mg–ethinyl estradiol 17.4 mg (Annovera®)Inserted for 3 weeks and removed for a 1-week interval during which time a withdrawal bleed occurs. The ring is cleaned and stored in a provided case during this week. The same ring is reinserted and can be used for a total of 13 cyclesCan be used for extended cycling by keeping the ring in the vagina with no ring-free interval. However, should be removed once a month for brief cleansing with warm water and a gentle cleanserDesigned to stay in place during sex; however, it can be removed for up to 2 hoursIf the ring is removed for more than 2 hours, abstinence or a backup method is necessary until it has been replaced for 7 consecutive days
Comprehensive overview of the recently FDA-approved contraceptive vaginal ring releasing segesterone acetate and ethinylestradiol: A new year-long, patient controlled, reversible birth control method
Published in Expert Review of Clinical Pharmacology, 2019
The most critical component that accounts for the success of this new CVR is the new progestin segesterone acetate. Segesterone acetate is a 19-nor-progesterone derivative, known as 19-norpregn-4-ene-3,20-dione, 17-hydroxy-16-methylene-19-nonpregn-4-ene-3,20-dione acetate ester and 16-methylene-17α-acetoxy-19-nor-pregn-4-ene-3,20-dione (see Figure 3). Its molecule formula is C23H3004 (see Figure 3). It is a white or yellowish-white powder with a molecular weight of 370.5 Dalton. This compound has significant potency; only low doses are needed for ovulation suppression. However, it is rapidly metabolized when administered orally, so a slow release, transdermal or transmucosal delivery system, such as the contraceptive vaginal ring, represents an excellent delivery system to utilize its strengths [11].
Advances in contraceptive vaginal rings: what does the future hold?
Published in Expert Opinion on Pharmacotherapy, 2018
Ilza Monteiro, Cristina Falbo Guazzelli, Luis Bahamondes
A new CVR that can be used for 1 year (even in a 21/7 cycle) must reduce the total cost. The progestin used, segesterone acetate, is less fully absorbed by the oral route. Its vaginal use may be highly beneficial in lactating women because it could benefit the new-born infant [72]. In breastfeeding mothers, however, the vaginal ring with segesterone acetate and without estrogen may be a good option because, during lactation, there is potentially better bleeding control, which is one of the side effects related to estrogen-free CVRs.
The use of progestin subdermal implants in the management of endometriosis-related pain symptoms and quality of life: a systematic review
Published in Current Medical Research and Opinion, 2022
Kristin Ambacher, Michael Secter, Ari P. Sanders
In this systematic review of 11 articles (3 RCTs, 6 observational studies, and 2 case series) involving 335 women with confirmed endometriosis, we found that the segesterone- and etonogestrel-releasing progestin subdermal implants led to significant improvements in cyclic and non-cyclic pain scores17–27, and quality of life18,19,24.